Kornimate/medical-research-clean huggingface dataset:
impact of enhanced external counterpulsation on vascular hemodynamics and status

Conditions: Coronary Heart Disease

Summary: the present study aimed to investigated the effect of enhanced external counterpulsation (eecp) on vascular hemodynamics and atherosclerosis, and the underlying shear stress related mechanisms

patients with coronary heart disease will be randomized into two groups: standard medical treatment and standard medical treatment plus eecp intervention. hemodynamic parameters, vascular status and function will be measured.

Eligibility criteria:
inclusion criteria: * more than 50% stenosis of left main trunk and 3 epicardial coronary arteries and their large branches showed by coronary angiography * or history of myocardial infarction * or history of prior revascularization * signed informed consent to participate in the study exclusion criteria: * clinically significant valvular heart disease * aortic aneurysm * congenital heart disease * acute myocarditis * arrythmias significantly interfere with the triggering of the eecp device * history of cerebral hemorrhage * hemorrhagic disease * lower limb infection, phlebitis * deep venous thrombosis * malignant disease * inr \> 2.5 * uncontrolled hypertension, defined as sbp \> 180mmhg or dbp \> 110mmhg * pregnancy

Keywords: coronary heart disease atherosclerosis vascular endothelium counterpulsation, external
3 simple questions to predict labor pain and epidural analgesia use in parturients

Conditions: Labor Pain

Summary: labor pain is complex to understand and challenging to define because of the interaction of multiple maternal and fetal factors. poorly controlled acute post-procedural pain may result in harmful physiological and psychological consequences for both mother and baby. it is therefore important to understand the prelabor factors that may affect the labour pain to facilitate the intrapartum pain management. the goal of this prospective observational study is to verify if expectations regarding pain experience translate to actual pain outcomes for women who are undergoing induction of labor.

a prospective observational cohort study. 100 parturients having induction of labor that match inclusion criteria will be asked to participate. after written informed consent, vital signs and patient demographics will be obtained and recorded. a 3 question survey will be given. patients will be asked to rate, using a 0-10 cm visual analog scale (vas), their anxiety level ("on a scale of 0-10 cm, with 0 being not anxious at all through 10 being extremely anxious, how anxious are you about your upcoming labor and delivery?"), their anticipated pain ("on a scale of 0-10, with 0 being no pain at all and 10 being pain as bad as you can imagine, how much pain do you anticipate experiencing during your upcoming labor and delivery?"), and using a categorical scale, to rate their anticipated epidural analgesic need ("on a scale of 0-5, with 0 being none at all, 1 being much less than average, 2 being less than average, 3 being average, 4 being more than average, and 5 being much more than average, how much epidural pain medication do you anticipate needing during your upcoming labor and delivery?"). then 24 hours after delivery, patient vas scores will be recorded, number of boluses, total number of hours of labor, patient comfort level and satisfaction

Eligibility criteria:
inclusion criteria: 1. the patient is 18 years or older 2. asa class ii or iii according to the 2014 american society of anesthesiologists' physical status classification 3. the patient is having induction of labor 4. the patient is having a singleton pregnancy 5. the fetus's gestational age is more than 37 weeks 6. the patient is considering having epidural analgesia. exclusion criteria: 1. the patient has refused to participate 2. there is a language barrier between the patient and the investigator 3. the patient received narcotics within the last two hours 4. the patient has chronic pain issues 5. there is significant concern about maternal or fetal welfare 6. the patient has a history of opioid tolerance 7. the patient has major psychiatric problem, 8. there is contraindication to epidural labor analgesia 9. patient has allergy to local anesthetics.
repurposing the antipsychotic drug chlorpromazine as adjuvant therapeutic agent for resected stage iii colon cancer

Conditions: Colon Cancer Stage III

Summary: chlorpromazine displays a series of remarkable bio-molecular effects in cancer cells, as inhibition of cell growth, nuclear aberrations, inhibition of the phosphoinositide 3-kinase/mammilian target of rapamycin (pi3k/mtor) axis, induction of cytotoxic autophagy, inhibition of glutamate and drd2 receptors. this study will evaluate the addition of chlorpromazine to the first-line therapeutic protocol in colon cancer stage iii.


Eligibility criteria:
inclusion criteria: * patients age ≥18 years old. * patients with histologically confirmed surgically resected stage iii colon cancer * no rectal cancer * stage iii disease (any pt, n1-2, m0) * patients should have a good performance status according to eastern cooperative oncology group (ecog) score (ecog 0-2). * patients with normal organic function as defined for the following criteria: * aspartate aminotransferase (ast), alanine aminotransferase (alt) ≤ 2.5 times the upper normal limit of the local laboratory (lsn-ll); * total serum bilirubin ≤ 2.0 x uln-ll; * absolute neutrophil count ≥ 1,500 / mm3; * platelet count ≥ 100,000 / mm3; * hemoglobin ≥ 8.0 g / dl; * serum creatinine ≤ 1.5 x uln-ll * patients should undergone curative-intent complete surgical resection * patients have at least one month from any major surgery to start of intervention * written informed consent before enrollment exclusion criteria: * patients with concurrent other malignancy or history of other malignancy treated within the past 3 years (other than non-melanoma skin cancer or in-situ cervical cancer) * patients with metastatic disease * patients who scheduled to receive any form of further adjuvant cancer therapy (a malignancy currently under active therapy * pregnant or breast-feeding patients * patients with known hypersensitivity or intolerance to cpz * patients with serious illness or psychiatric condition. * patients have current participation in other protocols with experimental drugs. * patients with no ability to ingest food orally. * patients who have familial adenomatous polyposis, hereditary non-polyposis rectal cancer, or inflammatory bowel disease * patients who are taken other chemoprevention drugs (ex. nsaids, aspirin)
observational of emergence time between patients receive general anesthesia with bis or spectrogram eeg monitor

Conditions: General Anesthetic Drug Adverse Reaction; Perioperative/Postoperative Complications

Summary: the bispectral index parameter is used to guide the titration of general anesthesia, however; conflicting results between different studies cannot prove the benefit of eeg monitor on improvement of or efficiency. next generation sedline features an enhanced signal processing engine, which provides processed eeg parameters. this four channel eeg monitor for the monitoring of perioperative anesthesia depth prevent overdose of medication and may help for individualized anesthetic plan. this research intended to observe the emergence time from end of the surgical wound closure to patient awake (or to extubation) with or without sedline.

this is a clinical observation study. inclusion criteria are patients with asa 1-3, age over 20 who need general anesthesia surgery without other neurologic disease. all inclusions will receive the general anesthesia with sedline monitor, a researcher who is not participated in the clinical practice will record the emergence characters and the eeg monitor signal. the controls were patients with same criteria without bis monitor. sample size was decided if the estimated difference between sedline group and bis group are 1 minute and the average estimated as 2 minute. with 80% desired power and default is .05, each group will need 63 cases.

Eligibility criteria:
inclusion criteria: * patients who need routine general anesthesia * have no neurological problem * have no dermo issue over forehead area * not allergic to the patch exclusion criteria: * patients who is not agreed
development and validation of a questionnaire to measure the impact of sbs and its treatments on patients' lives

Conditions: SBS - Short Bowel Syndrome

Summary: today, patients express a very strong need to take into account the consequences of their disease and its treatments in their therapeutic follow-up. it is therefore essential to better understand the needs, expectations and values of patients with sbs in order to better understand the impact of the disease on their lives, and thus improve the conditions for medical, social, psychological and technical care. the clinical expertise of health professionals and meetings with patient associations demonstrate the major gap between the parameters taken into account by physician to evaluate the evolution of the sbs and the day-to-day experience of the disease perceived by the patient. the objective of the artemis-gc study is to develop and validate an instrument to measure the impact of sbs and its treatments on daily life from the perspective of patients.


Eligibility criteria:
inclusion criteria: * patients with sbs defined by a hail length remaining in post-duodenal \< 2 meters * patients with intestinal insufficiency, i.e. chronic malabsorption requiring energetic and/or hydro-electrolytic intravenous support for more than 6 months * patients with a period of at least 6 months after the establishment of the sbs * patients who has already had a return home after the establishment of the sbs for a period of at least 3 months exclusion criteria: * patients with intestinal insufficiency but with a cause other than sbs * lack of understanding of the study * not speaking french
effect of foot massage on postpartum comfort and pain level of the mothers who had vaginal birth

Conditions: Postpartum Disorder; Massage

Summary: background and purpose: this study aims to investigate the effect of foot massage in the postpartum period on the need of receiving analgesic medication after assessing the postpartum comfort and pain status of the mothers who had vaginal delivery.materials and methods: the study was completed with 66 mothers. as data collection tools, a questionnaire, postpartum comfort scale (pcs), visual analogue scale (vas) and drug follow-up card (dfc) were used.

background and purpose: this study aims to investigate the effect of foot massage in the postpartum period on the need of receiving analgesic medication after assessing the postpartum comfort and pain status of the mothers who had vaginal delivery. materials and methods: in order to keep the number of people in balance between the groups, "block randomization" method which is one of the fixed probability randomization types was preferred. the research was completed with 66 persons, 33 in the study group and 33 in the control group. as data collection tools, a questionnaire, postpartum comfort scale (pcs), visual analogue scale (vas) and drug follow-up card (dfc) were used. research inclusion criteria include (i) primipara mothers (who had their first birth), (ii) mothers who had normal vaginal delivery, (iii) those who had undergone episiotomy, (iv) who were volunteered to participate in the study, (v) who were on the first day of delivery (first 24 hours), (vi) who had no complications in the infant and the baby, (vii) age of whom ranged from 18 to 35, (viii) those who did not apply or receive any other complementary therapy, (ix) mothers who did not have any wound, infection or discomfort etc. on their feet, and those who can read and write.

Eligibility criteria:
inclusion criteria: * primipara mothers (who had their first birth), * mothers who had normal vaginal delivery, * those who had undergone episiotomy, * who were volunteered to participate in the study, * who were on the first day of delivery (first 24 hours), * who had no complications in the infant and the baby, * age of whom ranged from 18 to 35, * those who did not apply or receive any other complementary therapy, * mothers who did not have any wound, infection or discomfort etc. on their feet, * mothers who can read and write exclusion criteria: * mothers with any systemic disease * mothers who dislike foot massage during practice * early discharge mothers * mothers who applied another massage technique * mothers who take the analgesic drug unnecessarily

Keywords: analgesia massage midwifery pain postpartum period
mckenzie exercise vs harmonic technique in chronic low back pain

Conditions: Low Back Pain

Summary: the purpose of this study was to investigate the effects of ht compared with mck exercise on pain and disability in patients with lbp.


Eligibility criteria:
inclusion criteria: * had persistent back pain at least eight weeks or during the last year subjects must suffer from lbp at least three times and each time lasted more than a week. exclusion criteria: * had a history of fracture or surgery in the spine, pelvis and lower extremities through last year * history of neuromuscular disease * the referral and radicular pain in the lower extremities and neurological or sensory disturbance in the lower extremities * urinary incontinence and pain severity higher that 7 based on visual analogue scale (vas)

Keywords: harmonic technique, low back pain, mckenzie exercise, pain, disability
nasal saline irrigation after radiation therapy for oropharyngeal cancer

Conditions: Nasal Obstruction; Rhinitis, Vasomotor; Epistaxis

Summary: the purpose of this study is to learn whether nasal saline irrigation is beneficial to patients undergoing radiation therapy for oropharyngeal cancer.

in this study, subjects are randomized to one of two study arms. they are either randomized to receive nasal saline irrigation treatment (treatment group) or not to receive any nasal irrigation treatment (control group). subjects randomized to the treatment group will be provided with saline packets to mix with water. all study subjects will be asked to complete questionnaires during the study. if a subject completes all study related activities, their total length of participation in the study will last about 2 months.

Eligibility criteria:
inclusion criteria: * all patients seen in the kumc ear, nose and throat clinic with oropharyngeal cancer that have undergone radiation therapy as the primary treatment exclusion criteria: * patients that are at high risk for infection secondary to nasal irrigation * patients with autoimmune disease or immune deficiency
study of bencycloquidium bromide nasal spray in the treatment of moderate-severe persistent allergic rhinitis

Conditions: Allergic Rhinitis

Summary: 450 subjects with moderate-severe persistent allergic rhinitis will be enrolled in the trial and divided into three groups for different treatments. group a：subjects with bencycloquidium bromide nasal spray, group b：subjects with mometasone furoate aqueous nasal spray, group c：subjects with bencycloquidium bromide nasal spray in combination with mometasone furoate aqueous nasal spray.the main purpose of the trial is to evaluate the efficacy of bencycloquidium bromide nasal spray alone or in combination with mometasone furoate aqueous nasal spray in the treatment of moderate-severe persistent allergic rhinitis and rhinorrhea.

the secondary purpose is to evaluate the effectiveness of bencycloquidium bromide nasal spray alone or in combination with mometasone furoate aqueous nasal spray in the treatment of moderate-severe persistent allergic rhinitis with nasal itching, nasal congestion, and sneezing. and evaluate the safety of bencycloquidium bromide nasal spray alone or in combination with mometasone furoate aqueous nasal spray.

Eligibility criteria:
inclusion criteria: * the diagnosis of allergic rhinitis meets the standards of "guidelines for the diagnosis and treatment of allergic rhinitis" (2015, tianjin); * the previous or current symptom onset is ≥4d/week and ≥4 consecutive weeks; the symptoms are severe or serious (total nasal symptom scores≥6 points) with single symptom score of runny nose ≥2 points; * able to complete the symptom score as required; * subjects voluntarily participate in this study, and sign a written informed consent form. use study drugs, complete evaluation and follow-up in accordance with the requirements of this study. exclusion criteria: * those who are known to be allergic to the ingredients contained in test drugs. * used vasoconstrictors within 1 day; used topical or oral antihistamines within 3 days; used topical glucocorticoids and leukotriene receptor antagonists within 7 days; used oral glucocorticoid drugs within 30 days. * those who have been diagnosed as asthma or have asthma symptoms (wheezing, shortness of breath, chest tightness, coughing). * patients suffering from respiratory infections or abnormal nasal anatomy (such as nasal polyps, nasal septum deviation, etc.) one month before enrollment. * received immunotherapy and nasal surgery within 6 months before enrollment. * patients with dry eye. * patients with glaucoma. * patients with enlarged prostate who have difficulty urinating. * people with mental disorders or impaired consciousness. * pregnancy (patients report pregnancy), those who have a pregnancy plan within 6 months, and lactating women. * patients considered by the researcher to be unsuitable to participate in this study.

Keywords: allergic rhinitis bencycloquidium bromide nasal spray
data registry of auto immune hemolytic anemia

Conditions: Autoimmune Hemolytic Anemia

Summary: in autoimmune hemolytic anemia (aiha) auto-antibodies directed against red blood cells (rbcs) lead to increased rbc clearance (hemolysis). this can result in a potentially life-threatening anemia. aiha is a rare disease with an incidence of 1-3 per 100,000 individuals. an unsolved difficulty in diagnosis of aiha is the laboratory test accuracy. the current 'golden standard' for aiha is the direct antiglobulin test (dat). the dat detects autoantibody- and/or complement-opsonized rbcs. the dat has insufficient test characteristics since it remains falsely negative in approximate 5-10% of patients with aiha, whereas a falsely positive dat can be found in 8% of hospitalized individuals. also apparently healthy blood donors can have a positive dat. the consequences of dat positivity are not well known and may point to early, asymptomatic disease, or to another disease associated with formation of rbc autoantibodies, such as a malignancy or (systemic) autoimmune disease. currently, there are no guidelines to follow-up dat positive donors. a second unsolved difficulty is the choice of treatment in aiha. hemolysis can be stopped or at least attenuated with corticosteroids, aiming to inhibit autoantibody production and/or rbc destruction. many patients do not respond adequately to corticosteroid treatment or develop severe side effects. currently, it is advised to avoid rbc transfusions since these may lead to aggravation of hemolysis and rbc alloantibody formation. but in case symptomatic anemia occurs, rbc transfusions need to be given. an evidence-based transfusion strategy for aiha patients is needed to warrant safe transfusion in this complex patient group. to design optimal diagnostic testing and (supportive) treatment algorithms, the investigators will study a group well-characterized patients with aiha and blood donors without aiha, via a prospective centralized clinical data collection and evaluation of new laboratory tests. with this data the knowledge of the aiha pathophysiology and to evaluate diagnostic testing in correlation with clinical features and treatment outcome can be improved.


Eligibility criteria:
inclusion criteria: * sufficient comprehension of the dutch language * signed informed consent by patient and/or parent/caretaker or donor * patients older than 3 months * patients with a positive dat, a positive eluate and signs of hemolysis\* * patients with a positive dat with complement only, negative eluate, but with signs of hemolysis * donors with a (repeatedly) positive dat and a positive eluate and/or clinically relevant cold auto-antibodies exclusion criteria: * prior inclusion in the draiha study
sensory sensitivity and urinary symptoms in the female population

Conditions: Bladder Pain and Discomfort; Urinary Urgency and Frequency; Bothersome Symptoms

Summary: bladder pain and discomfort, as well as urinary urgency and frequency, are bothersome symptoms seen frequently in the general population. clinical diagnostic terms used to describe these symptoms include interstitial cystitis (ic), bladder pain syndrome (bps), chronic prostatitis, and overactive bladder (oab), but there is tremendous overlap between these entities, and the distinction between them is based more on eminence than evidence. pain and/or sensory sensitivity has been suspected to play a role in the pathogenesis of both bladder pain and urinary urgency/frequency. however, no previous studies have investigated whether entities such as ic/bps and oab might merely represent different points in a continuum of bladder sensory sensitivity. moreover, we know of no studies that have directly compared sensory sensitivity in the bladder to global (i.e. cns-mediated) sensory sensitivity. in the study, a team of investigators with complementary expertise will perform a population-based study assessing bladder and overall sensory sensitivity, in a cohort of women representative of the population with respect to the entire continuum of bladder pain (from none to severe), and symptoms of urgency/frequency. these individuals will undergo urodynamics to measure sensory sensitivity in the bladder, as well as pressure pain and auditory loudness thresholds. the specific aims are to demonstrate: 1) sensory sensitivity in the bladder is related to sensory sensitivity elsewhere in the body, suggesting a cns-driven mechanism, and 2) individuals in the population with greater global sensory sensitivity will display: a) more bladder pain, b) more urgency/frequency, and c) other symptoms of centrally-mediated pain states, such as pain in regions other than the bladder, fatigue, and insomnia.


Eligibility criteria:
inclusion criteria: * at least 18 years old exclusion criteria: * 1) neurological disease or disorder affecting the bladder; 2) previous augmentation cystoplasty or cystectomy; 3) systemic autoimmune disorder (such as crohn's disease or ulcerative colitis, lupus, rheumatoid arthritis; 4)history of pelvic cancer (colon, bladder, uterus, ovary); 5) current major psychiatric disorder or other psychiatric or medical issues that would interfere with study participation (e.g. dementia, psychosis, upcoming major surgery, etc); 6) current pregnancy. these exclusion criteria will be assessed at the time of the initial telephone interview.